Alesta Therapeutics key facts
- Developer of small-molecule biotech program designed for the development of innovative therapies targeting synthetic lethal metabolic dependencies in cancer.
- It has raised $68.3M; the latest was Early Stage VC ($68.3M) in Dec 2024.
- Notable investors include Frazier Healthcare Partners, Novartis Venture Fund, RTW Investments, Droia Ventures, RV Invest — 7 tracked in total.
- Status: Privately Held (backing).
- ·Watch Alesta Therapeutics: the Monday email on marks, rounds and moves
Alesta Therapeutics funding rounds
No funding rounds for Alesta Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Alesta Therapeutics investors
7 investors are on record for Alesta Therapeutics, including Frazier Healthcare Partners, Novartis Venture Fund, RTW Investments and Droia Ventures.
About Alesta Therapeutics
Developer of small-molecule biotech program designed for the development of innovative therapies targeting synthetic lethal metabolic dependencies in cancer. The company targets a control mechanism involved in the stress response pathways required for cancer cell survival, enabling patients to shut down pathways that have a particular dependency on cancer cell growth.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2021
- Employees
- 7
- Website
- alestatherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Alesta Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.